Organon (OGN) Change in Account Payables (2020 - 2026)
Organon (OGN) posted quarterly Change in Account Payables of $32.0 million for Q1 2026, up 121.48% year-over-year from $14.4 million in Q1 2025, and up 126.67% on a QoQ basis from -$120.0 million in Q4 2025.
Organon (OGN) Change in Account Payables (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Change in Account Payables for 7 consecutive years, with $32.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 121.48% year-over-year to $32.0 million; the TTM figure through Mar 2026 stood at -$36.0 million (down 183.72% YoY), while the FY2025 annual figure was -$217.0 million, down 38.22% from the prior year.
- Change in Account Payables came in at $32.0 million for Q1 2026 at Organon, up from -$120.0 million in the prior quarter.
- The five-year high for Change in Account Payables was $293.0 million in Q2 2024, with the low at -$349.0 million in Q1 2024.
- Average Change in Account Payables over 5 years is -$24.5 million, with a median of $12.0 million recorded in 2025.
- Across the five-year window, Change in Account Payables sank 7550.0% in 2022 and soared 168.6% in 2023, its largest moves.
- Year by year, Change in Account Payables stood at $86.0 million in 2022, then soared by 168.6% to $231.0 million in 2023, then tumbled by 74.89% to $58.0 million in 2024, then sank by 306.9% to -$120.0 million in 2025, then soared by 126.67% to $32.0 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $32.0 million, -$120.0 million, and $12.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 571.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -67.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 32.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.00 Mn |
| Mar 31, 2026 | 32.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Dec 31, 2025 | -120.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Sep 30, 2025 | 12.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 40.00 Mn |
| Mar 31, 2025 | -149.00 Mn |
| Mar 31, 2025 | -149.00 Mn |
| Dec 31, 2024 | 58.00 Mn |
| Dec 31, 2024 | 58.00 Mn |
| Sep 30, 2024 | -159.00 Mn |
| Sep 30, 2024 | -159.00 Mn |
| Jun 30, 2024 | 293.00 Mn |
| Jun 30, 2024 | 293.00 Mn |
| Mar 31, 2024 | -349.00 Mn |
| Mar 31, 2024 | -349.00 Mn |
| Dec 31, 2023 | 231.00 Mn |
| Dec 31, 2023 | 231.00 Mn |